Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study, HYPER-H21-4, may be the first-ever study to indicate a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral cannabidiol (“CBD”) therapy. The study is evaluating Lexaria’s patented DehydraTECH(TM)-CBD capsule formulation. LEXX reported that study results showed exceptional safety and tolerability and statistically significant lowering of 24-hour ambulatory BP as well as BP lowered for the duration of the entire five-week study. The study also indicated lowered BP for patients currently taking other antihypertensive drugs as well as patients not taking any other antihypertensive drugs. According to the announcement, Lexaria is aware of only a few other published stories designed to evaluate whether a sustained decrease in resting BP is possible following multiple weeks of oral CBD dosing, with none of those studies showing successful results. “That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” said Lexaria Bioscience Corp. CEO Chris Bunka in the press release. “DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study. Indeed, of the handful of minor, nonserious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD. Consistent with Lexaria’s often-mentioned, de-risking strategy, this exceptional safety profile should prove beneficial as we prepare for our planned upcoming phase Ib Investigational New Drug clinical study to be registered with the U.S. Food and Drug Administration.”
To view the full press release, visit https://ibn.fm/uEM2e
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php